Loading
Pharmacology and Obesity Treatment / Diabetes Treatment and Management · Journal article
Diabetes Therapy · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a protocol and baseline characteristics paper from an ongoing Phase 3 randomized controlled trial of survodutide in Chinese adults with overweight or obesity. The trial is designed to evaluate percentage change in body weight and achievement of ≥5% body weight reduction by week 52, but no efficacy or safety results are reported here; readers should await the primary outcomes analysis.
Multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. Chinese adults with BMI ≥28 kg/m² or BMI ≥24 kg/m² and at least one obesity-related complication.. Intervention: Once-weekly subcutaneous survodutide 3.6 mg or 4.8 mg plus lifestyle intervention. Compared with: Placebo plus lifestyle intervention. n = 306. China (multicenter).
Trial enrolled 306 participants randomized 1:1:1 to survodutide 3.6 mg, survodutide 4.8 mg, or placebo once-weekly for 76 weeks. Baseline mean BMI 33.2 kg/m², body weight 93.9 kg, waist circumference 105.6 cm, triglycerides 2.2 mmol/L. 72.9% had at least one obesity-related complication: metabolic dysfunction-associated steatotic liver disease (48.4%), dyslipidemia (42.2%), hypertension (27.8%), type 2 diabetes (16.7%), obstructive sleep apnea (4.6%), cardiovascular disease (4.2%); 19.6% had prediabetes.
No efficacy or safety outcomes are reported; this is a baseline and design paper only. Primary outcome results at week 52 and full 76-week safety data not yet available.
This is a study design document; no clinical guidance can be drawn until efficacy and safety data are published. Clinicians should await the primary outcomes report to inform decisions about survodutide in Chinese populations.
This is a design and baseline characteristics report of an ongoing Phase 3 trial with no efficacy or safety results reported; it describes the study protocol and enrolled population but cannot yet support clinical claims.
As stated by the source record.
Quoted from the source exactly as published.
This is a study design document; no clinical guidance can be drawn until efficacy and safety data are published. Clinicians should await the primary outcomes report to inform decisions about survodutide in Chinese populations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
We aimed to describe the rationale, design, and overall baseline characteristics of the trial evaluating the efficacy, safety, and tolerability of survodutide in Chinese adults with overweight or obesity (SYNCHRONIZE™-CN, NCT06214741). In this 76-week, multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, Chinese participants were randomized 1:1:1 to once-weekly subcutaneous survodutide (3.6 mg or 4.8 mg) or placebo plus lifestyle intervention. Participants with either body mass index (BMI) ≥ 28 kg/m 2 or BMI ≥ 24 kg/m 2 and at least one obesity-related complication were eligible. The primary endpoints were the percentage change in body weight and achievement of body weight reduction ≥ 5% from baseline to week 52. At baseline, participants ( N = 306) had a mean age of 36.9 years, body weight 93.9 kg, waist circumference 105.6 cm, BMI 33.2 kg/m 2, triglycerides 2.2 mmol/L. 49% were women. 72.9% had at least one obesity-related complication, with metabolic dysfunction‑associated steatotic liver disease (48.4%), dyslipidemia (42.2%), hypertension (27.8%), and type 2 diabetes mellitus (16.7%) being the most prevalent, followed by obstructive sleep apnea (4.6%) and cardiovascular diseases (4.2%). In total, 19.6% had prediabetes. This trial was designed to provide a robust evaluation of efficacy and safety of survodutide for the treatment of obesity or overweight in Chinese adults. Clinical Trials.gov identifier, NCT06214741.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.